MKI67 and metastatic neoplasm: The two deaths in the cohort were attributable to metastatic disease progression and occurred at 3.8 months (in the context of poor prognostic factors, including NEC Ki67 95%, FDG-avid and high burden disease) and 118 months post PRRT.